Table 6 The effects of BRAF V600E mutation on progression in multiple PTC patients
BRAFv600E mutation | All negative | All positive | Mixed | P value |
|---|---|---|---|---|
Number | 61 | 40 | 35 | Â |
Age ≤ 14 | 15 (24.6%) | 1 (2.5%) | 1 (2.9%) | 0.001 |
Tall cell variant | 3 (4.9%) | 8 (20.0%) | 6 (17.1%) | 0.597 |
Extrathyroidal invasion | 10 (16.4%) | 17 (42.5%) | 8 (22.9%) | 0.214 |
Vascular invasion | 3 (4.9%) | 8 (20.0%) | 4 (11.4%) | 0.097 |
Hashimoto’s thyroiditis | 12 (19.7%) | 14 (35.0%) | 10 (28.6%) | 0.088 |
Lymph node metastasis | 27 (44.3%) | 32 (80.0%) | 15 (42.9%) | < 0.001 |
Distant metastasis | 1 (1.6%) | 3 (7.5%) | 2 (5.7%) | 0.065 |
10-year survival rate | 56 (91.8%) | 35 (87.5%) | 34 (97.1%) | 0.336 |